The results of a seven-year research project suggest that there may be a new approach to treating one of the most common and devastating forms of brain cancer in adults – glioblastoma multiforme (GBM).

In a peer-reviewed study published BMC cancer, Scientists from the University of Sureya show that the short chain of amino acids (peptide HTL-001) is effective for targeting and inhibiting the function of the family of genes responsible for the growth of GBM-Hox genes. The study was conducted on cellular and animal models.

The HTL-001 peptide used in the study has been tested for safety and is suitable for testing in patients. These tests are now being considered in GBM and other cancers.

Hardew Panda, project a presenter and professor of medical oncology at Sureya University, said:

“People with glioblastoma multiforme have a 5 percent five-year survival rate, a figure that hasn’t improved in decades. While we’re still at the beginning of the process, our seven-year project gives a glimmer of hope for a solution the Hox gene, which is linked to the growth of GBM and other cancers, and which has proved elusive as a target for years. ”

Ironically, the Hox genes are responsible for the healthy growth of brain tissue, but are usually attenuated at birth after active activity in a growing embryo. However, if they are again inappropriately “included”, their activities can lead to progression cancer. Hox gene dysregulation has long been recognized in GBM.

The project was implemented in collaboration with the Universities of Surrey, Leeds and Texas and HOX Therapeutics, a start-up company of the University of Surrey based in the University’s research park.

Professor Susan Short, co-author of the study from the University of Leeds, said:

“We desperately need new ways to treat these aggressive brain tumors. Targeted developmental genes such as HOX genes which are abnormally included in tumor cells may be a new and effective way to stop the growth of glioblastoma and become life-threatening. ”

James Calverwell, CEO of HOX Therapeutics, said:

“HOX Therapeutics is excited to be involved with this project, and we hope that with our continued support, this research will eventually lead to new and effective treatments for both brain and other cancers where HOX gene overexpression is evident. therapeutic purpose ”.